This year at ISC19, Dr. Eliezer Masliah MD highlighted key ongoing trials on vascular cognitive impairment and dementia (VCID) in Alzheimer’s disease (AD)1. Currently, there are 140 AD trials at different stages of development covering a wide array of topics that include pharmacological, neuropsychiatric or caregiver interventions. Many of the pharmacological trials target vascular interactions … Read more
The International Stroke Conference 2019 (ISC19) was packed with all things stroke. In my previous blogs I outlined the expectations and highlights from the daily goings on in Hawaii. Here I will summarize the Willis Lecture presented by Frank Ray Sharp, MD, FAHA entitled “Molecular Markers and Mechanisms of Stroke.” ISC19 is a premier setting … Read more
Over the last decade, several direct oral anticoagulants have become available for thromboembolic prophylaxis, as an alternative to the Vitamin K antagonist warfarin. These agents are either direct thrombin inhibitors (dabigatran) or Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban). In my clinical practice, I frequently prescribe these medications for stroke prophylaxis from atrial fibrillation. During these … Read more
Cardiovascular diseases such as diabetes and hypertension are established risk factors for mild cognitive impairment (MCI) and vascular dementia (VD). Vascular pathology occurs alongside neurodegenerative disease pathology, and both are associated with interactive effects on the clinical presentation of VD1. Several cardiovascular risk factors of VD could be modified during the preclinical course of the … Read more
Getting to Hawaii was quite the event! I underestimated the flight and how I would feel with such time zone changes. However, the International Stroke Conference 2019 (#ISC19) was worth all the efforts. The meeting objectives were sufficiently described in the program book and my previous blog. As promised, there were sessions to equip scientists … Read more
Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes and is associated with a high early mortality and poor long term functional outcomes. It is the only subtype of stroke which still does not have a proven and effective treatment available. Clinical trials investigating craniotomy and surgical evacuation of the hematoma have not shown improvement … Read more
The International Stroke Conference 2019 (ISC19) is held in conjunction with the International Society of Cerebral Blood Flow and Metabolism (ISCBFM) this year. This session promises a unique learning opportunity. The meeting expectations is for participants to be exposed to the most recent advances in basic stroke and how it translates into clinical research. Additionally, … Read more
(In anticipation of the International Stroke Conference 2019 – ISC19) Not so long ago, the benefit of endovascular thrombectomy beyond six hours of ischemic stroke onset was uncertain, particularly among patients with ischemic brain tissue that has not yet undergone infarction. The volume of irreversibly injured ischemic tissue and the volume of brain tissue that … Read more